Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
An important goal of current neuroleptic research is to develop antipsychotic compounds with the low incidence of extrapyramidal side effects. The therapeutic success and less side-effect of atypical anti-psychotics such as clozapine and risperidone has focused the attention on the role of receptor systems other than dopaminergic system in the pathophysiology of neuroleptics-associated extrapyramidal side effects. The present study compares the effect of chronic administration of typical and atypical antipsychotics on neurochemical profile in rat forebrain. The study was planned to study changes in extracellular levels of norepinephrine, dopamine and serotonin in forebrain region of brain and tried to correlate them with hyperkinetic motor activities (vacuous chewing movements (VCM's), tongue protrusions and facial jerking) in rats, hall mark of chronic extrapyramidal side-effect of neuroleptic therapy tardive dyskinesia. Chronic administration of haloperidol (1 mg/kg) and chlorpromazine (5 mg/kg) resulted in significant increase in orofacial hyperkinetic movements where as clozapine and risperidone showed less significant increase in orofacial hyperkinetic movements as compared to control. There were also significant decrease in the extracellular levels of neurotransmitters dopamine, norepinephrine and serotonin in fore-brain as measured by HPLC/ED after chronic administration of haloperidol and chlorpromazine. Chronic administration of atypical neuroleptics clozapine and risperidone resulted in the decrease in extracellular concentration of dopamine and norepinephrine but the effect was less significant as compared to typical drugs. However, treatment with atypical neuroleptics resulted in 3 fold increase in serotonin levels as compared to forebrain of control rats. Typical and atypical neuroleptics showed varying effects on neurotransmitters, especially serotonin which may account for the difference in their profile of side effects (Tardive dyskinesia).
Bishnoi
Mahendra
M
Centre with Potential for Excellence in Biomedical Sciences, Panjab University, Chandigarh 160 014, India.
Kumar
Anil
A
Chopra
Kanwaljit
K
Kulkarni
Shrinivas K
SK
D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001835:Body Weight / Q000187:drug effects; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects; D004298:Dopamine / Q000032:analysis; D004409:Dyskinesia, Drug-Induced / Q000473:pathology; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D009638:Norepinephrine / Q000032:analysis; D016548:Prosencephalon / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects; D012701:Serotonin / Q000032:analysis
D014150:Antipsychotic Agents; D012701:Serotonin; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine